Table 3 Risk of prostate cancer death and PSA relapse by statin use after ADT initiation in a cohort of prostate cancer patients treated with ADT.
Risk of prostate cancer death | |||||
|---|---|---|---|---|---|
No of participants/deaths | Age-adjusted | Multivariable adjusted | 1-year lag-time | 3-year lag-time | |
Statin use after ADT | HR (95% CI) | HR (95% CI)* | HR (95% CI)* | HR (95% CI)* | |
None | 2707/582 | Reference | Reference | Reference | Reference |
Any | 1721/252 | 0.68 (0.59–0.80) | 0.82 (0.69–0.96) | 0.89 (0.76–1.04) | 0.90 (0.77–1.06) |
Intensity of statin use (DDDs/year) | |||||
First tertile (below 92 DDD/year) | 574/160 | 0.83 (0.61–1.14) | 0.94 (0.69–1.29) | 0.99 (0.71–1.37) | 0.86 (0.58–1.29) |
Second tertile (92–210 DDD/year) | 572/70 | 0.60 (0.47–0.75) | 0.67 (0.53–0.84) | 0.73 (0.57–0.93) | 0.87 (0.67–1.15) |
Third tertile (above 210 DDD/year) | 575/22 | 0.48 (0.37–0.63) | 0.58 (0.44–0.76) | 0.88 (0.69–1.14) | 0.93 (0.68–1.26) |
Risk of PSA relapse | |||||
Statin use after ADT | No of participants/PSA relapses | Age-adjusted | Multivariable adjusted* | 1-year lag-time | 3-year lag-time |
None | 2707/957 | Reference | Reference | Reference | Reference |
Any | 1721/608 | 0.65 (0.58–0.72) | 0.73 (0.65–0.82) | 0.85 (0.76–0.95) | 0.97 (0.86–1.09) |
